Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Quiz|Articles|March 8, 2026
Dermatology Times Spot Test: March 8, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A weekly quiz format is used to reinforce dermatology knowledge through short, topical question sets.
- The current focus highlights psoriasis news, emphasizing updates relevant to clinical decision-making and evolving standards of care.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test.
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. In this edition, we’ll cover the latest news on
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
What proportion of patients with psoriasis in the US also have obesity or overweight with at least one weight-related comorbidity?
CT-P43 is a biosimilar to which biologic therapy?
Which data source was used to identify patients in this real-world analysis of tildrakizumab?
Advertisement
Related to this article
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
4
Alopecia Areata Awareness Month: 2026 in Review
5